Lilly Inks Deal With BioMS For Phase III Multiple Sclerosis Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration valued at $497 million plus royalties aims to develop, commercialize synthetic peptide MBP8298, Lilly tells “The Pink Sheet” DAILY.
You may also be interested in...
Lilly/BioMS Forge Ahead With MS Drug After Phase II/III Interim Look
Dirucotide gets positive nod from DSMB; Lilly to pay $10 million milestone to BioMS.
Lilly/BioMS Forge Ahead With MS Drug After Phase II/III Interim Look
Dirucotide gets positive nod from DSMB; Lilly to pay $10 million milestone to BioMS.
Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market
With more than $5 billion operating cash flow, firm is looking for promising in-licensing candidates, CEO Lechleiter says.